Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Journal of Biological Macromolecules

• Publication date

  2018-01-09

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ijbiomac.2017.12.162PMID 29329808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.

  2017cited by this paper
• Synthesis and Biological Testing of Novel Glucosylated Epigallocatechin Gallate (EGCG) Derivatives

  2016cited by this paper
• Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.

  2015cited by this paper
• Computational analyses of curcuminoid analogs against kinase domain of HER2

  2014cited by this paper
• Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.

  2014cited by this paper
• Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents

  2014cited by this paper
• Differences in the Binding Affinities of ErbB Family: Heterogeneity in the Prediction of Resistance Mutants

  2013cited by this paper
• Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model

  2013cited by this paper
• In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.

  2013cited by this paper
• Antibacterial and Antifungal Activities of New Acylated Derivatives of Epigallocatechin Gallate

  2012cited by this paper
• Semisynthesis of Fluoro-substituted Benzoates of Epi-gallocatechin

  2012cited by this paper
• Oxidative stability of (-)-epigallocatechin gallate in the presence of thiols.

  2012cited by this paper
• MMPBSA.py: An Efficient Program for End-State Free Energy Calculations.

  2012cited by this paper
• Identification of Potent EGFR Inhibitors from TCM Database@Taiwan

  2011cited by this paper
• Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

  2011cited by this paper
• Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

  2011cited by this paper
• EGFR pathway in advanced non-small cell lung cancer.

  2011cited by this paper
• Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine- and estrogen-induced α9-nicotinic acetylcholine receptor upregulation in human breast cancer cells.

  2011cited by this paper
• EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED THERAPIES FOR SOLID TUMOURS

  2011cited by this paper
• EGFR Signaling and Drug Discovery

  2010cited by this paper
• Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

  2010cited by this paper
• Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

  2009cited by this paper
• Quantitative prediction of fold resistance for inhibitors of EGFR.

  2009cited by this paper
• Managing protein flexibility in docking and its applications.

  2009cited by this paper
• Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2

  2009cited by this paper
• Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.

  2009cited by this paper
• The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells.

  2008cited by this paper
• Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

  2008cited by this paper
• Enhanced anti-influenza A virus activity of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives: effect of alkyl chain length.

  2008cited by this paper
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

  2008cited by this paper
• Receptor tyrosine kinases: mechanisms of activation and signaling.

  2007cited by this paper
• A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer.

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.

  2007cited by this paper
• Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis

  2007cited by this paper
• Enzymatic synthesis and characterization of novel epigallocatechin gallate glucosides

  2006cited by this paper
• Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

  2006cited by this paper
• An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

  2006cited by this paper
• Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

  2006cited by this paper
• Synthesis, structure analyses, and characterization of novel epigallocatechin gallate (EGCG) glycosides using the glucansucrase from Leuconostoc mesenteroides B-1299CB.

  2006cited by this paper
• Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.

  2006cited by this paper
• Targeting Tyrosine Kinases in Cancer: The Second Wave

  2006cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006cited by this paper
• Synthesis and antibacterial activity of hydrolytically stable (−)-epicatechin gallate analogues for the modulation of β-lactam resistance in Staphylococcus aureus

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• The Amber biomolecular simulation programs

  2005cited by this paper
• (−)-Epigallocatechin Gallate and Polyphenon E Inhibit Growth and Activation of the Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Signaling Pathways in Human Colon Cancer Cells

  2005cited by this paper
• Synthesis and antibacterial activity of hydrolytically stable (-)-epicatechin gallate analogues for the modulation of beta-lactam resistance in Staphylococcus aureus.

  2005cited by this paper
• Overview of the Tolerability of Gefitinib (IRESSA™) Monotherapy

  2004cited by this paper
• Development and testing of a general amber force field

  2004cited by this paper
• Exploring protein native states and large‐scale conformational changes with a modified generalized born model

  2004cited by this paper
• A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

  2004cited by this paper
• Protein flexibility in ligand docking and virtual screening to protein kinases.

  2004cited by this paper
• Converging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf

  2004cited by this paper
• A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG].

  2004cited by this paper
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2004cited by this paper
• A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations

  2003cited by this paper
• Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.

  2003cited by this paper
• Protein flexibility is an important component of structure-based drug discovery.

  2002cited by this paper
• Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor*

  2002cited by this paper
• The PyMOL Molecular Graphics System

  2002cited by this paper
• Mechanism-based design of a protein kinase inhibitor

  2001cited by this paper
• The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

  2001cited by this paper
• Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Correspondence e-mail:

  2000cited by this paper
• Alpha-anomer-selective glucosylation of (+)-catechin by the crude enzyme, showing glucosyl transfer activity, of Xanthomonas campestris WU-9701.

  2000cited by this paper
• Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models.

  2000cited by this paper
• Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

  1995cited by this paper
• Enzymatic Syntheses of Two Stable (-)-Epigallocatechin Gallate-glucosides by Sucrose Phosphorylase

  1995cited by this paper
• Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems

  1993cited by this paper
• The Syntheses of Catechin-glucosides by Transglycosylation with Leuconostoc mesenteroides Sucrose Phosphorylase

  1993cited by this paper
• Comparative protein modelling by satisfaction of spatial restraints.

  1993cited by this paper
• Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.

  1987cited by this paper
• Molecular dynamics with coupling to an external bath

  1984cited by this paper
• Comparison of simple potential functions for simulating liquid water

  1983cited by this paper
• ALGORITHMS FOR MACROMOLECULAR DYNAMICS AND CONSTRAINT DYNAMICS

  1977cited by this paper

• Insight into the inhibitory activity of mangiferin and Silybin against HER2 and EGFR using theoretical and experimental approaches

  2025cites this paper
• Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents.

  2024cites this paper
• Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation

  2024cites this paper
• Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study

  2023cites this paper
• Pharmacophore modeling, Virtual screening, Molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approach

  2022cites this paper
• Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR

  2022cites this paper
• Structural Insight of the Anticancer Properties of Doxazosin on Overexpressing EGFR/HER2 Cell Lines

  2021cites this paper
• Endogenous tumor microenvironment-responsive multifunctional nanoplatforms for precision cancer theranostics

  2021cites this paper
• Structural insights into SARS-CoV-2 spike protein and its natural mutants found in Mexican population

  2021cites this paper
• Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2

  2021influential citation
• Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights

  2021cites this paper
• Topomer-CoMFA proposed as a tool to construct dual EGFR/HER-2 models

  2021cites this paper
• In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.

  2021cites this paper
• Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2

  2021cites this paper
• Antiangiogenesis Potential of Alpinumisoflavone as an Inhibitor of Matrix Metalloproteinase-9 (MMP-9) and Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)

  2020cites this paper
• Molecular insights into how SHBG dimerization exerts changes on ligand molecular recognition.

  2020cites this paper
• Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2

  2019influential citation
• Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors

  2019cites this paper
• CDK4 as a phytochemical based anticancer drug target

  2019cites this paper
• Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants

  2019cites this paper
• Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis.

  2018cites this paper
• Selective mechanisms and molecular design of 2,4 Diarylaminopyrimidines as ALK inhibitors.

  2018cites this paper